Subscribe To
Bluebird's (blue) scd studies clinical hold lifted by the fda
bluebird (BLUE) announces that the partial clinical hold on studies evaluating lovo-cel for sickle cell...
December 20, 2022, 10:32 am
Jeffrey sonnenfeld's top ceos of 2022
Jeff Sonnenfeld, Yale School of Management senior associate dean for leadership studies, joins 'Power L...
December 19, 2022, 3:32 pm
Fifa world cup: ‘sponsors were very pleased,' professor says
NYU School of Professional studies Academic Director and Professor Daniel Kelly joins Yahoo Finance Liv...
December 19, 2022, 1:19 pm
Blue stock alert: what to know as the fda lifts hold on bluebird bio treatment
Sometimes, the financial markets can be highly unpredictable. Reportedly, the U.S. Food and Drug Administration (FDA) lifted its partial clinical hold...
December 19, 2022, 11:50 am
Barrick says massive reko diq project gets all clear, targets first production for 2028
(Kitco News) - Barrick said it is currently updating the project's 2010 feasibility and 2011 feasibility expansion ...
December 15, 2022, 5:36 pm
Ngm bio gives presentation featuring preclinical characterization of ngm936 at 2022 ash annual meeting
–NGM936, a ILT3 x CD3 bispecific T cell engager product candidate, potently induced T cell dependent cytotoxicity (TDCC) against ILT3+ AML cells whi...
December 13, 2022, 12:00 am
Eur/usd: firm break of key fibo barrier to neutralize warnings from weekly chart
The Euro regained traction in early Monday’s trading after Friday’s close in red, and attacks again key Fibo barrier at 1.0578 (38.2% of 1.2266/0....
December 12, 2022, 3:12 pm
Agios presents updated pyrukynd® (mitapivat) long-term extension data demonstrating sustained clinical benefits in adults with pyruvate kinase (pk) deficiency at 64th ash annual meeting and exposition
– Data Suggest Long-term Treatment with PYRUKYND® in Adults with PK Deficiency is Associated with Improvements in Hemoglobin, Iron Overload, Transf...
December 12, 2022, 12:00 am
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T studies Evaluating PYRUKYND® in Adults with Non...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T studies Evaluating PYRUKYND® in Adults with Non...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T studies Evaluating PYRUKYND® in Adults with Non...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T studies Evaluating PYRUKYND® in Adults with Non...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T studies Evaluating PYRUKYND® in Adults with Non...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T studies Evaluating PYRUKYND® in Adults with Non...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T studies Evaluating PYRUKYND® in Adults with Non...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T studies Evaluating PYRUKYND® in Adults with Non...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T studies Evaluating PYRUKYND® in Adults with Non...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T studies Evaluating PYRUKYND® in Adults with Non...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T studies Evaluating PYRUKYND® in Adults with Non...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T studies Evaluating PYRUKYND® in Adults with Non...
December 10, 2022, 11:30 pm